Cannabis Research

A division of Medicinal Organic Cannabis Australia (MOCA)

Welcome to Research Cannabis by Medicinal Organic Cannabis Australia (MOCA) , your go-to source for the latest information on medical cannabis research. We are a team of dedicated professionals who are passionate about advancing the field of medical cannabis research and education. Our goal is to provide up-to-date and accurate information on the latest research findings related to medical cannabis.

At Research Cannabis, we understand the importance of medical cannabis research in the treatment of various medical conditions. We strive to provide a platform for researchers, clinicians, and patients to share their findings, experiences, and knowledge. Our team is committed to providing unbiased and evidence-based information to help individuals make informed decisions about medical cannabis use.

Whether you are a patient, clinician, researcher, or simply interested in learning more about medical cannabis, we invite you to explore our website and discover the latest research and news in the field.

At Research Cannabis, we are committed to advancing the field of medical cannabis research. We believe that the use of medical cannabis in the treatment of various medical conditions has the potential to improve the lives of millions of people worldwide.

Our team of experts is dedicated to staying up-to-date with the latest research findings related to medical cannabis. We carefully review and analyze peer-reviewed studies, clinical trials, and other relevant research to provide our readers with accurate and unbiased information.

We cover a wide range of topics related to medical cannabis research, including:

Our team is committed to providing accurate and up-to-date information to help individuals make informed decisions about medical cannabis use. We invite you to explore our website and discover the latest research and news in the field.

Medical cannabis research has gained significant traction in recent years, offering promising therapeutic potential for various conditions. At MOCA Health, our commitment to evidence-based practice drives our exploration into the applications of cannabinoids in health care.

Cannabis compounds like cannabidiol (CBD) and tetrahydrocannabinol (THC) interact with the body\u2019s endocannabinoid system, influencing inflammation, pain perception, appetite, and mood regulation. Research highlights their use in conditions such as acne, where cannabinoids reduce inflammation and sebum production (Ol\u00e1h et al., 2014). ADHD symptoms, including hyperactivity and impulsivity, may be alleviated through the modulation of dopamine release by cannabinoids (Cooper et al., 2017).

Neurodegenerative diseases like Alzheimer\u2019s also show potential for treatment with cannabis, as studies suggest a reduction in amyloid-beta plaques and neuroinflammation (Aso & Ferrer, 2014). Similarly, appetite stimulation by THC has proven beneficial for anorexia and cachexia associated with chronic illness (Haney et al., 2007). Anxiety management is another significant area, with CBD demonstrating anxiolytic effects without intoxication (Blessing et al., 2015).

For arthritis and other inflammatory conditions, cannabis provides pain relief and reduced swelling, presenting an alternative to opioids (Fitzcharles et al., 2020). Emerging research also points to its role in Autism Spectrum Disorder (ASD), where cannabinoids may help mitigate anxiety and aggression (Aran et al., 2019). In oncology, cannabis alleviates chemotherapy-induced nausea, stimulates appetite, and manages cancer-related pain (Abrams & Guzman, 2015).

Studies are investigating cannabis\u2019s cardiovascular implications, including blood pressure regulation and cardioprotection (Pacher et al., 2006). Additionally, chronic pain, a major focus of cannabis research, benefits from cannabinoids\u2019 ability to modulate pain pathways, particularly in neuropathic conditions (Wilsey et al., 2013). For epilepsy, CBD has shown remarkable efficacy in reducing seizure frequency, leading to FDA approval of Epidiolex for specific syndromes (Devinsky et al., 2017).

Cannabis also holds promise in mental health, with evidence of antidepressant effects linked to serotonin receptor interaction (El-Alfy et al., 2010). Its utility in improving sleep quality is supported by its sedative properties in certain strains (Babson et al., 2017). Across these areas, cannabis\u2019s role in palliative care is vital, addressing complex symptoms like pain, mood, and appetite loss in terminal illnesses (Bar-Sela et al., 2013).

MOCA Health\u2019s research aims to harness these findings to develop personalized, effective treatment plans for patients. By integrating clinical data and scientific advancements, we are unlocking the potential of medical cannabis to transform health care.

References:


Medicinal Organic Cannabis Australia (MOCA) is a leading producer and supplier of organic premium grade cannabis. Our focus is on research and development of cannabis based products to alleviate symptoms from recognised conditions. International and local research on cannabis derivatives form the basis of our operations.

With operations in Australia, New Zealand snd our state of the art cultivation and research facility in Sardinia Italy, we are constantly looking at how to bring innovation and knowhow to the medical cannabis industry. 

Patients, book your appointment to visit with your medical practitioners, MOCA Health offers cannabis based therapies for a number of health conditions.